SIG-1451, a Novel, Non-Steroidal Anti-Inflammatory Compound, Attenuates Light-Induced Photoreceptor Degeneration by Affecting the Inflammatory Process

Yuki Kikuchi, Eriko Sugano, Shiori Yuki, Kitako Tabata, Yuka Endo, Yuya Takita, Reina Onoguchi, Taku Ozaki, Tomokazu Fukuda, Yoshihiro Takai, Takahiro Kurose, Kōichi Tanaka, Yoichi Honma, E. Pérez, Maxwell Stock, José R. Fernández, Masanori Tamura, Michael Voronkov, Jeffry B. Stock, Hiroshi TomitaInternational Journal of Molecular Sciences 2022 · DOI

TL;DR

This study investigates SIG-1451, a novel anti-inflammatory compound, for its protective effects against light-induced photoreceptor degeneration, a key factor in age-related macular degeneration (AMD). The research demonstrates that SIG-1451 partially preserves retinal structure and function by dampening the inflammatory response, particularly microglial activation and the upregulation of inflammatory genes.

What Problem Does This Paper Address?

Age-related macular degeneration (AMD) is a leading cause of blindness, characterized by progressive degeneration of photoreceptor cells in the retina. While dry AMD lacks effective treatments, understanding its underlying mechanisms is crucial. Light-induced photoreceptor degeneration serves as a valuable model to study these mechanisms, mimicking aspects of dry AMD. Inflammation, particularly involving microglia and Müller cells, has been implicated in the progression of AMD and photoreceptor damage. However, the precise role of specific inflammatory pathways and potential therapeutic interventions targeting them remain areas of active research. This paper aims to address this by evaluating the efficacy of SIG-1451, an anti-inflammatory compound, in mitigating light-induced photoreceptor damage and elucidating its mechanism of action.

Methods

The study employed a multi-pronged approach combining in vivo and in vitro experiments.

  • In vivo model: Sprague Dawley rats were exposed to intense light (1000 lx for 24 hours) to induce photoreceptor degeneration. SIG-1451 was administered intraperitoneally daily before light exposure.
  • Retinal Structure and Function Assessment:
    • Optical Coherence Tomography (OCT): Used to measure retinal thickness, specifically the inner limiting membrane to retinal pigment epithelium (ILM-RPE) and outer nuclear layer (ONL) thicknesses, providing a non-invasive way to assess structural damage.
  • Electroretinography (ERG): Employed to evaluate retinal function by measuring the electrical response of photoreceptor cells to light stimuli.
  • Immunohistochemistry: Used to visualize and quantify the expression of specific markers:
  • Iba-1: A marker for microglia, to assess microglial activation and infiltration into retinal layers.
  • GFAP: A marker for glial cells, to assess astrogliosis, a reactive response of glial cells.
  • Gene Expression Analysis (RT-qPCR): Quantified the mRNA levels of inflammatory-related genes (e.g., TLR4, CCL2, C3, CCR2) in retinal tissue and cultured cells.
  • In vitro model: Immortalized rat retinal Müller cells (rMC-1) were stimulated with lipopolysaccharide (LPS), a Toll-like receptor 4 (TLR4) agonist, to mimic inflammatory conditions.
  • Western Blotting: Analyzed protein levels and phosphorylation status of key inflammatory signaling molecules, including TLR4, NF-κB, and I-κB.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • SIG-1451 as a Potential Therapeutic for AMD: The compound shows promise in protecting photoreceptors from light-induced damage, a relevant model for dry AMD, suggesting a potential avenue for treating this debilitating condition.
  • Inflammation as a Key Driver of Secondary Damage: The study strongly suggests that SIG-1451's protective effects are primarily mediated by its anti-inflammatory actions, rather than directly preventing initial photoreceptor cell death. This highlights the critical role of inflammation in exacerbating light-induced damage.
  • Targeting Microglial Activation: SIG-1451 significantly suppressed Iba-1 immunoreactivity, indicating a reduction in microglial activation. This is a crucial finding, as activated microglia are known to contribute to retinal inflammation and degeneration.
  • Modulation of Inflammatory Gene Expression: The compound effectively inhibited the upregulation of inflammatory genes like CCL2 and CCR2 following light exposure and LPS stimulation, underscoring its broad anti-inflammatory impact.
  • Inhibition of the NF-κB Pathway: The reduction in phosphorylated I-κB levels in SIG-1451 treated cells points to the compound's ability to interfere with the NF-κB signaling pathway, a central regulator of inflammatory responses.

Key Results

  • Structural Preservation: SIG-1451 treatment partially preserved retinal thickness, particularly the outer nuclear layer (ONL), which contains photoreceptor nuclei, in rats exposed to light damage.
  • Functional Improvement: ERG recordings showed that SIG-1451 administration led to significantly larger a-wave and b-wave amplitudes 3 days after light exposure, indicating improved retinal function compared to saline-treated controls.
  • Reduced Microglial Infiltration: Immunohistochemical analysis revealed significantly lower Iba-1 immunoreactivity in SIG-1451 treated retinas, indicating suppressed microglial activation.
  • Inhibition of Inflammatory Gene Upregulation: RT-qPCR demonstrated that SIG-1451 inhibited the light-induced upregulation of genes like CCL2 and CCR2 in retinal tissue and CCL2 in cultured Müller cells.
  • NF-κB Pathway Modulation: Western blot analysis showed that SIG-1451 treatment decreased the levels of phosphorylated I-κB in LPS-stimulated Müller cells, suggesting inhibition of NF-κB activation.

Limitations and Future Work

  • Indirect Protective Mechanism: The authors emphasize that SIG-1451 appears to act indirectly by attenuating inflammatory progression rather than directly preventing initial photoreceptor cell death. Further studies are needed to fully elucidate the direct effects, if any, on photoreceptor survival.
  • Specific Cell Type Involvement: While the study used Müller cells in vitro, the in vivo experiments suggest SIG-1451 might also affect other retinal cells like macrophages and RPE cells, as CCR2 expression was suppressed in LD-retinas but not detected in cultured Müller cells. Future work could investigate the precise cell types targeted by SIG-1451 in vivo.
  • Dosage and Timing: The study used specific dosages and treatment timings. Further optimization of these parameters could potentially enhance the protective effects.
  • Long-term Effects: The study primarily focused on short-term effects (1-8 days post-light exposure). Investigating the long-term efficacy and safety of SIG-1451 would be crucial for its clinical translation.
  • Clinical Translation: While promising, SIG-1451 is still a candidate drug. Further preclinical and clinical trials are necessary to establish its safety and efficacy in humans for AMD treatment.

Summary updated

Abstract

Age-related macular degeneration is a progressive retinal disease that is associated with factors such as oxidative stress and inflammation. In this study, we evaluated the protective effects of SIG-1451, a non-steroidal anti-inflammatory compound developed for treating atopic dermatitis and known to inhibit Toll-like receptor 4, in light-induced photoreceptor degeneration. SIG-1451 was intraperitoneally injected into rats once per day before exposure to 1000 lx light for 24 h; one day later, optical coherence tomography showed a decrease in retinal thickness, and electroretinogram (ERG) amplitude was also found to have decreased 3 d after light exposure. Moreover, SIG-1451 partially protected against this decrease in retinal thickness and increase in ERG amplitude. One day after light exposure, upregulation of inflammatory response-related genes was observed, and SIG-1451 was found to inhibit this upregulation. Iba-1, a microglial marker, was suppressed in SIG-1451-injected rats. To investigate the molecular mechanism underlying these effects, we used lipopolysaccharide (LPS)-stimulated rat immortalised Müller cells. The upregulation of C-C motif chemokine 2 by LPS stimulation was significantly inhibited by SIG-1451 treatment, and Western blot analysis revealed a decrease in phosphorylated I-κB levels. These results indicate that SIG-1451 indirectly protects photoreceptor cells by attenuating light damage progression, by affecting the inflammatory responses.
BibTeX
@article{kikuchi2022sig,
  author = {Yuki Kikuchi and Eriko Sugano and Shiori Yuki and Kitako Tabata and Yuka Endo and Yuya Takita and Reina Onoguchi and Taku Ozaki and Tomokazu Fukuda and Yoshihiro Takai and Takahiro Kurose and Kōichi Tanaka and Yoichi Honma and E. Pérez and Maxwell Stock and José R. Fernández and Masanori Tamura and Michael Voronkov and Jeffry B. Stock and Hiroshi Tomita},
  title = {{SIG-1451, a Novel, Non-Steroidal Anti-Inflammatory Compound, Attenuates Light-Induced Photoreceptor Degeneration by Affecting the Inflammatory Process}},
  journal = {International Journal of Molecular Sciences},
  year = {2022},
  doi = {10.3390/ijms23158802},
}
Figure